PE Hub has spotted seven private equity deals involving franchises in the past six months. Here’s a look at the deals, ...

Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization, is set to be acquired by GHO Capital Partners and ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

Rowley Law PLLC is investigating potential securities law violations by Avid Bioservices, Inc. and its board of directors concerning the proposed acquisition of the company by GHO Capital Partners LLP ...

Nektar Therapeutics today reported financial results for the third quarter ended September 30, 2024. Cash and investments ...

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Avid Bioservices (CDMO – Research Report) today. The company’s shares ...

RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company ...

The frozen burrito business unit could fetch up to $400m and is expected to appeal to mid-market private equity firms.

Avid Bioservices shares were up 12% at $12.25 after getting a buyout offer from GHO Capital Partners and Ampersand Capital Partners. Under the terms of the buyout, Avid will be acquired by funds ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth $1.1 billion. “In evaluating ...